Centers for Disease Control and Prevention Centers for Disease Control and Prevention CDC Home Search CDC CDC Health Topics A-Z site search
National Office of Public Health Genomics
Centers for Disease Control and Prevention
Office of Genomics and Disease Prevention
Site Search

Family History

This paper was published with modifications in Prim Care, 2004; 31(3):711-37
“The findings and conclusions in this report are those of the author(s) and do not necessarily represent the views of the funding agency.”

Clinical Application of Genetic Risk Assessment Strategies for Coronary Artery Disease: Genotypes, Phenotypes, and Family History

by Maren T. Scheuner, MD, MPH


Download print version Link here to download free Adobe Reader (3.31MB)

line

arrow 1 | 2 | 3

References

  1. American Heart Association. Heart and stroke statistics: 2003 update. Dallas (TX): American Heart Association; 2002.
  2. Scheuner MT. Genetic predisposition to coronary artery disease. Curr Opin Cardiol 2001;16:251-60.  
  3. Tavani A, Augustin L, Bosetti C, et al. Influence of selected lifestyle factors on risk of acute myocardial infarction in subjects with familial predisposition for the disease. Prev Med 2004;38:468-72.  
  4. Berenson GS, Srinivasan SR, Bao W, Newman III WP, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med 1998;338:1650-6.  
  5. Lefkowitz RJ, Willerson JT. Prospects for cardiovascular research. JAMA 2001;285:581-7.  
  6. Weissberg PL. Atherogenesis: current understanding of the causes of atheroma. Heart 2000;83:247.  
  7. Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med 2001;134:224-38.  
  8. Scheuner MT. Genetic evaluation for coronary artery disease. Genet Med 2003;5:269-85.  
  9. Ridker PM, Stampfer MJ. Assessment of genetic markers for coronary thrombosis: promise and precaution. Lancet 1999;353:687-8.  
  10. Girelli D, Russo C, Ferraresi P, et al. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med 2000;343:774-80.  
  11. Folsom AR, Wu KK, Rosamond WD, Sharrett AR , Chambless LE. Prospective study of the hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1997;96:1102-8.  
  12. Weiss EJ, Bray PF, Tayback M, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996;334:1090-4.  
  13. Carter AM, Ossei-Gerning N, Grant PJ. Platelet glycoprotein IIIa Pl A polymorphism in young men with myocardial infarction. Lancet 1996;348:485-6.  
  14. Carter AM, Ossei-Gerning N, Wilson IJ, Grant PJ. Association of the platelet Pl A polymorphism of glycoprotein IIb/IIIa and fibrinogen beta 448 polymorphism with myocardial infarction and extent of coronary artery disease. Circulation 1997;96:1424-31.  
  15. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. Pl A1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997;349:385-8.  
  16. Herrmann SM, Poirier O, Marques-Vidal P, et al. The Leu 33/Pro polymorphism (PlA1/A2) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM Study. Thromb Haemost 1997;77:1170-81.  
  17. Laule M, Cascorbi I, Stangl V, Blelecke C, et al. A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: a case-control study. Lancet 1999;353:708-12.  
  18. Cooke GE, Bray PF, Hamlington JD, Pham DM, Goldschmidt-Clermont PJ. Pl A2 polymorphism and efficacy of aspirin. Lancet 1998;351:1253.  
  19. Pujukanta P, Cargill M, Viitanen L, et al. Two loci on chromosomes 2 and X for premature coronary heart disease identified in early- and late-settlement populations of Finland . Am J Hum Genet 2000;67:1481-93.  
  20. Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 1995;377:744-7.  
  21. Harrap SB, Zammit KS, Wong ZYH, et al. Genome-wide linkage analysis of the acute coronary syndrome suggests a locus on chromosome 2. Arterioscler Thromb Vasc Biol 2002;22:874-8.  
  22. Lange LA, Lange EM, Bielak LF, et al. Autosomal genome-wide scan for coronary artery calcification loci in sibships at high risk for hypertension. Arterioscler Thromb Vasc Biol 2002;22:418-22.  
  23. Gudmundsson G, Matthiasson SE, Arason H, et al. Localization of a gene for peripheral arterial occlusive disease to chromosome 1p31. Am J Hum Genet 2002;70:586-92.  
  24. Bray MS, Krushkal J, Li L, et al. Positional genomic analysis identifies the beta-adrenergic receptor gene as a susceptibility locus for human hypertension. Circulation 2000;101:2877-82.  
  25. Krushkal J, Xiong M, Ferrell R, Sing CF, Turner ST, Boerwinkle E. Linkage and association of adrenergic and dopamine receptor genes in the distal portion of the long arm of chromosome 5 with systolic blood pressure variation. Hum Mol Genet 1998;7:1379-83.  
  26. Krushkal J, Ferrell R, Mockrin SC, Turner ST, Sing CF, Boerwinkle E. Genome-wide linkage analyses of systolic blood pressure using highly discordant siblings. Circulation 1999;99:1407-10.  
  27. Williams RR, Hunt SC, Hopkins PN, Wu LL, Lalouel JM. Evidence for single gene contributions to hypertension and lipid disturbances: definition, genetics, and clinical significance. Clin Genet 1994;46:80-7.  
  28. Geller DS, Farhi A, Pinkerton N, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000;289:119-23.  
  29. Frossard PM, Lestringant GG, Malloy MJ, Kane JP. Human renin gene BglI dimorphism associated with hypertension in two independent populations. Clin Genet 1999;56:428-33.  
  30. Deng H-W, Deng H, Liu Y-J, et al. A genomewide linkage scan for quantitative-trait loci for obesity phenotypes. Am J Hum Genet 2002;70:1138-51.  
  31. Lee JH, Reed DR, Li W-D, et al. Genome scan for human obesity and linkage to markers in 20q13. Am J Hum Genet 1999;64:196-209.  
  32. Heinonen P, Koulu M, Pesonen U, et al. Identification of a three-amino acid deletion in the alpha-2B-adrenergic receptor that is associated with reduced basal metabolic rate in obese subjects. J Clin Endocrinol Metab 1999;84:2429-33.
  33. Large V, Hellstrom L, Reynisdottir S, et al. Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. J Clin Invest 1997;100:3005-13.  
  34. Nagase T, Aoki A, Yamamoto M, et al. Lack of association between the trp64arg mutation in the beta-3-adrenergic receptor gene and obesity in Japanese men: a longitudinal analysis. J Clin Endocrinol Metab 1997;82:1284-7.  
  35. Mitchell BD, Blangero J, Comuzzie AG, et al. A paired sibling analysis of the beta-3 adrenergic receptor and obesity in Mexican Americans. J Clin Invest 1998;101:584-7.  
  36. Sina M, Hinney A, Ziegler A, et al. Phenotypes in three pedigrees with autosomal dominant obesity caused by haploinsufficiency mutations in the melanocortin-4 receptor gene. Am J Hum Genet 1999;65:1501-7.  
  37. Ristow M, Müller-Wieland D, Pfeiffer A, Krone W, Kahn CR. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 1998;339:953-9.  
  38. Walder K, Norman RA, Hanson RL, Schrauwen P, et al. Association between uncoupling protein polymorphisms (UCP2-UCP3) and energy metabolism/obesity in Pima Indians. Hum Mol Genet 1998;7:1431-5.  
  39. Busfield F, Duffy DL, Kesting JB, et al. A genomewide search for type 2 diabetes-susceptibility genes in indigenous Australians. Am J Hum Genet 2002;70:349-57.  
  40. Di Paola R, Frittitta L, Miscio G, et al. A variation in 3’UTR of hPTP1B increases specific gene expression and associates with insulin resistance. Am J Hum Genet 2002;70:806-12.  
  41. Lindgren CM, Mahtani MM, Widén E, et al. Genomewide search for type 2 diabetes mellitus susceptibility loci in Finnish families: the Botnia study. Am J Hum Genet 2002;70:509-16.  
  42. Horikawa Y, Oda N, Cox NJ, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000;26:163-75.  
  43. Vionnet N, Hani EH, Dupont S, et al. Genomewide search for type 2 diabetes-susceptibility genes in French Whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am J Hum Genet 2000;67:1470-80.  
  44. Ghosh S, Watanabe RM, Valle TT, et al. The Finland-United States investigation of non-insulin dependent diabetes mellitus genetics (FUSION) study: I. an autosomal genome scan for genes that predispose to type 2 diabetes. Am J Hum Genet 2000;67:1174-85.  
  45. Watanabe RM, Ghosh S, Langefeld CD, et al. The Finland-United States Investigation of non-insulin-dependent diabetes mellitus genetics (FUSION) study: II. an autosomal genome scan for diabetes-related quantitative-trait loci. Am J Hum Genet 2000;67:1186-200.  
  46. Stone LM, Kahn SE, Fujimoto WY, Deeb SS, Porte Jr. D. A variation at position −30 of the beta-cell glucokinase gene promoter is associated with reduced beta-cell function in middle-aged Japanese-American men. Diabetes 1996;45:422-8.  
  47. Hart LM, Stolk RP, Dekker JM, et al. Prevalence of variants in candidate genes for type 2 diabetes mellitus in the Netherlands: the Rotterdam study and the Hoorn study. J Clin Endocrinol Metab 1999;84:1002-6.
  48. Reis AF, Ye W-Z, Dubois-Laforgue D, Bellanne-Chantelot C, Timsit J, Velho G. Association of a variant in exon 31 of the sulfonylurea receptor 1 (SUR1) gene with type 2 diabetes mellitus in French Caucasians. Hum Genet 2000;107:138-44.  
  49. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPAR gamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000;26:76-80.  
  50. Soro A, Pajukanta P, Lilja HE, et al. Genome scans provide evidence for low-HDL-C loci on chromosomes 8q23, 16q24.1-24.2, and 20q13.11 in Finnish families. Am J Hum Genet 2002;70:1333-40.  
  51. Arya R, Duggirala R, Almasy L, et al. Linkage of high-density lipoprotein-cholesterol concentrations to a locus on chromosome 9p in Mexican Americans. Nat Genet 2002;30:102-5.  
  52. Peacock JM, Arnett DK, Atwood LD, et al. Genome scan for quantitative trait loci linked to high-density lipoprotein cholesterol: the NHLBI Family Heart Study. Arterioscler Thromb Vasc Biol 2001;21:1823-8.  
  53. Klos KL, Kardia SLR, Ferrell RE, Turner ST, Boerwinkle E, Sing CF. Genome-wide linkage analysis reveals evidence of multiple regions that influence variation in plasma lipid and apolipoprotein levels associated with risk of coronary heart disease. Arterioscler Thromb Vasc Biol 2001;21:971-8.
  54. Wang XL, Rainwater DL, VandeBerg JF, Mitchell BD, Mahaney MC. Genetic contributions to plasma total antioxidant activity. Arterioscler Thromb Vasc Biol 2001;21:1190-5.  
  55. Smith SC, Greenland P, Grundy SM. AHA Conference Proceedings: Prevention Conference V. Beyond secondary prevention: identifying the high-risk patient for primary prevention. Executive Summary. Circulation
    2000;101:111-6.  
  56. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.  
  57. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executuve summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.  
  58. Gertler MM, White PD. Coronary heart disease in young adults: a multidisciplinary study. Cambridge (MA): Harvard University Press; 1954.
  59. Thomas CB, Cohen BH. The familial occurrence of hypertension and coronary artery disease with observations concerning obesity and diabetes. Ann Intern Med 1955;42:90-127.  
  60. Rose G. Familial patterns in ischaemic heart disease. Br J Prev Soc Med 1964;18:75-80.  
  61. Slack J, Evans KA. The increased risk of death from ischaemic heart disease in first-degree relatives of 121 men and 96 women with ischaemic heart disease. J Med Genet 1966;3:239-57.  
  62. Rissanen AM. Familial occurrence of coronary heart disease: effect of age at diagnosis. Am J Cardiol 1979;44:60-6.  
  63. Hunt SC, Williams RR, Barlow GK. A comparison of positive family history definitions for defining risk of future disease. J Chron Dis 1986;39:809-21.
  64. Silberberg JS, Wlodarczyk J, Fryer J, Robertson R, Hensley MJ. Risk associated with various definitions of family history of coronary heart disease. The Newcastle Family History Study II. Am J Epidemiol 1998;147:1133-9.  
  65. Nora JJ, Lortscher RH, Spangler RD, Nora AH, Komberling WJ. Genetic-epidemiologic study of early-onset ischemic heart disease. Circulation 1980;61:503-8.  
  66. Brown DW, Giles WH, Burke W, Greenlund KJ, Croft JB. Familial aggregation of early-onset myocardial infarction. Community Genet 2002;5:232-8.  
  67. Frielander Y, Kark JD, Stein Y. Family history of myocardial infarction as an independent risk factor for coronary heart disease. Br Heart J 1985;53:382-7.  
  68. Sesso HD, Lee IM, Gaziano JM, Rexrode KM, Glynn RJ, Buring JE. Maternal and paternal history of myocardial infarction and risk of cardiovascular disease in men and women. Circulation 2001;104:393-8.  
  69. Sholtz RI, Rosenman RH, Brand RJ. The relationship of reported parental history to the incidence of coronary heart disease in the Western Collaborative Group Study. Am J Epidemiol 1975;102:350-6.  
  70. Colditz GA, Stampfer MJ, Willett WC, Rosner B, Speizer FE, Hennekens CH. A prospective study of parental history of myocardial infarction and coronary heart disease in women. Am J Epidemiol 1986;123:48-58.  
  71. Khaw KT, Barrett-Connor E. Family history of heart attack: A modifiable risk factor? Circulation 1986;74:239-44.  
  72. Schildkraut JM, Myers RH, Cupples LA, Kiely DK, Kannel WB. Coronary risk associated with age and sex of parental heart disease in the Framingham Study. Am J Cardiol 1989;64:555-9.  
  73. Phillips AN, Shaper AG, Pocock SJ, Walker M. Parental death from heart disease and the risk of heart attack. Eur Heart J 1988;9:243-51.  
  74. Hopkins PN, Williams RR, Kuida H, et al. Family history as an independent risk factor for incident coronary artery disease in a high-risk cohort in Utah. Am J Cardiol 1988;62:703-7.  
  75. Colditz GA, Rimm EB, Giovannucci E, Stampfer MJ, Rosner B, Willett WC. A prospective study of parental history of myocardial infarction and coronary artery disease in men. Am J Cardiol 1991;67:933-8.  
  76. De Jong SC, Stehouwer CDA, Mackaay AJC, et al. High prevalence of hyperhomocysteinemia and asymptomatic vascular disease in siblings of young patients with vascular disease and hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 1997;17:2655-62.  
  77. Margaglione M, Cappucci G, Colaizzo D, Vecchione G, Grandone E, Di Minno G. C-reactive protein in offspring is associated with the occurrence of myocardial infarction in first-degree relatives. Arterioscler Thromb Vasc Biol 2000;20:198-203.  
  78. Mills JD, Mansfield MW, Grant PJ. Tissue plasminogen activator, fibrin D-dimer, and insulin resistance in the relatives of patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol 2002;22:704-9.  
  79. Kareinen A, Viitanen L, Halonen P, Lehto S, Laakso M. Cardiovascular risk factors associated with insulin resistance cluster in families with early-onset coronary heart disease. Arterioscler Thromb Vasc Biol 2001;21:1346-52.  
  80. Kee F, Tiret L, Robo JY, et al. Reliability of reported family history of myocardial infarction. BMJ 1993;307:1528-30.
  81. Bensen JT, Liese AD, Rushing JT, et al. Accuracy of proband reported family history: the NHLBI Family Heart Study (FHS). Genet Epidemiol 1999;17:141-50.  
  82. Williams RR, Hunt SC, Heiss G, et al. Usefulness of cardiovascular family history data for population-based preventive medicine and medical research (the Health Family Tree Study and the NHLBI Family Heart Study). Am J Cardiol 2001;87:129-35.
  83. Scheuner MT, Wang S-J, Raffel LJ, Larabell SK, Rotter JI. Family history: a comprehensive genetic risk assessment method for the chronic conditions of adulthood. Am J Med Genet 1997;71:315-24.  
  84. Lamarche B, Lemieux I, Després JP. The small, dense LDL phenotype and the risk of coronary heart disease: Epidemiology, pathophysiology and therapeutic aspects. Diabetes Metab 1999;25:199-211.  
  85. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996;276:875-81.  
  86. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense LDL particles and the risk of ischemic heart disease: prospective results from the Québec Cardiovascular Study. Circulation 1997;95:69-75.  
  87. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276:882-8.  
  88. St-Pierre AC, Ruel IL, Cantin B, et al. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation 2001;104:2295-9.  
  89. Superko HR. Small, dense LDL subclass phenotype B: issues for clinicians. Curr Atheroscler Rep 1999;1:50-7.  
  90. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65.  
  91. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-5.  
  92. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative Observational Study. JAMA 2002;288:980-7.  
  93. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk 1998;5:229-32.  
  94. Tawacol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocysteinemia is associated with impaired endothelial-dependent vasodilation in humans. Circulation 1997;95:1191-211.  
  95. Mangoni AA, Jackson SH. Homocysteine and cardiovascular disease: current evidence and future prospects. Am J Med 2002;112:556-65.
  96. Desouza C, Keebler M, McNamara DB, Fonseca V. Drugs affecting homocysteine metabolism: impact on cardiovascular risk. Drugs 2002;62:605-16.  
  97. Ubbink JB. The role of vitamins in the pathogenesis and treatment of hyperhomocysteinemia. J Inherit Metab Dis 1997;20:315-25.  
  98. Malinow MR, Bostrom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the nutrition committee, American Heart Association. Circulation 1999;99:178-82.  
  99. Brattstrom LE, Israelsson B, Norrving B, et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease: effects of pyridoxine and folic acid treatment. Atherosclerosis 1990;81:51-60.  
  100. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss heart study: a randomized controlled trial. JAMA 2002;288:973-9.  
  101. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke (VISP) randomized controlled trial. JAMA 2004;291:565-75.  
  102. Baker F, Picton D, Blackwood S, et al. Blinded comparison of folic acid and placebo in patients with ischemic heart disease: an outcome trial. Circulation 2002;106(Suppl II):741S.  
  103. Stein JH, Rosenson RS. Lipoprotein Lp(a) excess and coronary heart disease. Arch Intern Med 1997;157:1170-6.  
  104. Jenner JL, Ordovas I, Lamon-Fava S, et al. Effects of age, sex and menopausal status on plasma lipoprotein(a) levels: The Framingham Offspring Study. Circulation 1993;87:1135-41.  
  105. Berg K. Lp(a) lipoprotein: a monogenic risk factor for cardiovascular disease. In: GoldbourtU, de FaireU, BergK, editors. Genetic factors in coronary heart disease Boston: Kluwer Academic Publishers; 1994. p. 275-87.
  106. Kraft HG, Lingenhel A, Kochl S, et al. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol 1996;16:713-9.  
  107. Marcovina SM, Kochinsky ML. Lipoprotein(a) concentration and apolipoprotein(a) size: a synergistic role in advanced atherosclerosis? Circulation 1999;100:1151-3.  
  108. Gurakar A, Hoeg JM, Kostner G, Papadopoulos NM, Brewer Jr. HB. Levels of lipoprotein(a) decline with neomycin and niacin treatment. Atherosclerosis 1985;57:293-301.  
  109. Temme EH, Mensink RP, Hornstra G. Comparison of the effects of diets enriched in lauric, palmitic, or oleic acids on serum lipids and lipoproteins in healthy women and men. Am J Clin Nutr 1996;63:897-903.  
  110. Thomas TR, Ziogas G, Harris WS. Influence of fitness status on very-low density lipoproteins subfractions and lipoprotein(a) in men and women. Metabolism 1997;46:1178-83.  
  111. Espeland MA, Marcovina SM, Miller V, et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Circulation 1998;97:979-86.  
  112. Zmuda JM, Thompson PD, Dickenson R, Bausserman LL. Testosterone decreases lipoprotein(a) in men. Am J Cardiol 1996;77:1244-7.  
  113. Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000;283:1845-52.  
  114. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995;274:1771-4.  
  115. Krauss RM. Dense low-density lipoproteins and coronary artery disease. Am J Cardiol 1995;75:53B-7B.  
  116. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988;260:917-21.  
  117. Griffin BA, Freeman DJ, Tait GW, et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994;106:241-53.  
  118. Dreon DM, Fernstrom HA, Williams PT, Krauss RM. LDL subclass phenotypes and lipoprotein response to a low-fat, high-carbohydrate diet in women. Arterioscler Thromb Vasc Biol 1997;17:707-14.  
  119. Superko HR, Krauss RM. Differential effects of nicotinic acid in subjects with different LDL subclass phenotypes. Atherosclerosis 1992;95:69-76.  
  120. Sakai T, Kamanna VS, Kashyap ML. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arteerioscler Thromb Vasc Biol 2001;21:1783-9.  
  121. Superko HR, Haskell WL, Krauss RM. Association of lipoprotein subclass distribution with use of selective and non-selective beta-blocker medications in patients with coronary heart disease. Atherosclerosis 1993;101:1-8.  
  122. Minihane AM, Khan S, Leigh-Firbank EC, et al. ApoE polymorphism and fish oil supplementation in subjects with atherogenic lipoprotein phenotype. Arterioscler Thromb Vasc Biol 2000;20:117-28.  
  123. Ito MK. Niacin-based therapy for dyslipidemia: past evidence and future advances. Am J Manag Care 2002;8(Suppl):S315-22.  
  124. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. JAMA 2002;287:356-9.  
  125. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.  
  126. Backes JM, Howard PA, Moriarty PM. Role of C-reactive protein in cardiovascular disease. Ann Pharmacother 2004;38:110-8.  
  127. Ridker PM, Morrow DA. C-reactive protein, inflammation, and coronary risk. Cardiol Clin 2003;21:315-25.  
  128. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100:230-5.  
  129. Maison P, Mennen L, Sapinho D, et al. A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration. Atherosclerosis 2002;160:155-60.  
  130. Harper CR, Jacobson TA. The fats of life: the role of omega-3 fatty acids in the prevention of coronary heart disease. Arch Intern Med 2001;161:2185-92.  
  131. Online Mendelian Inheritance in Man. OMIM. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD), 2000. Available at: http://www.ncbi.nlm.nih.gov/omim/. Accessed April 2003.
  132. Scheuner MT, Yoon P, Khoury MJ. Contribution of Mendelian disorders to common chronic disease: opportunities for recognition, intervention and prevention. Am J Med Genet 2004;125C:50-65.  
  133. Glazier AM, Nadeau JH, Aitman TJ. Finding genes that underlie complex traits. Science 2002;298:2345-9.  
  134. Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesterol ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med 1998;338:86-93.  
  135. Nieminen MS, Mattila KJ, Aalto-Setala K, et al. Lipoproteins and their genetic variation in subjects with and without angiographically verified coronary disease. Arteriosclerosis Thromb 1992;12:58-69.  
  136. E to M, Watanable K, Makino I. Increased frequencies of apolipoprotein E2 and E4 alleles in patients with ischemic heart disease. Clin Genet 1989;39:183-9.  
  137. Cumming AM, Robertson F. Polymorphism at the apoE locus in relation to risk of coronary heart disease. Clin Genet 1984;25:310-3.  
  138. Tikkanen MJ, Huttunen JK, Ehnholm C, Pietinen P. Apolipoprotein E4 homozygosity predisposes to serum cholesterol elevation during high fat diet. Arteriosclerosis 1990;10:285-8.  
  139. Lopez-Miranda J, Ordovás JM, Mata P, et al. Effect of apolipoprotein E phenotype on diet-induced lowering of plasma low density lipoprotein cholesterol. J Lipid Res 1994;35:1965-75.  
  140. Ordovás JM, Lopez-Miranda JM, Mata P, Perez-Jimenez F, Lichtenstein AH, Schaefer EJ. Gene-diet interaction in determining plasma lipid response to dietary intervention. Atherosclerosis 1995;118:S11-27.  
  141. Campos H, D'Angostino M, Ordovás JM. Gene-diet interactions and plasma lipoproteins: role of apolipoprotein E and habitual saturated fat intake. Genet Epidemiol 2001;20:117-28.  
  142. Denke MA, Adams-Huet B, Nguyen AT. Individual cholesterol variation in response to a margarine- or butter-based diet. JAMA 2000;284:2740-7.  
  143. Hokanson JE, Austin MA. Plasma triglyceride is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol: a meta analysis of population based studies. J Cardiovasc Risk 1996;3:213-9.  
  144. Roses AD. Apolipoprotein E affects the rate of Alzheimer disease expression: beta-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. J Neuropathol Exp Neurol 1994;53:429-37.  
  145. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer Disease. Statement on use of apolipoprotein E testing for Alzheimer disease. JAMA 1995;274:1627-9.  
  146. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrolfolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998;98:2520-6.  
  147. Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C-T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002;288:2023-31.  
  148. American Society of Human Genetics/American College of Medical Genetics Test and Technology Transfer Committee Working Group. ASHG/ACMG Statement: measurement and use of total plasma homocysteine. Am J Hum Genet 1998;63:1541-3.  
  149. Psaty BM, Smith NL, Lemaitre RN, et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA 2001;285:906-13.  
  150. Sen-Banerjee S, Siles X, Campos H. Tobacco smoking modifies association between Gln-Arg192 polymorphism of human paraoxonase gene and risk of myocardial infarction. Arterioscler Thromb Vasc Biol 2000;20:2120-6.  
  151. Moshfegh K, Wuillemin WA, Redondo M, et al. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction. Lancet 1999;353:351-4.  
  152. US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002;136:157-60.  
  153. Dwyer JH, Allayee H, Dwyer KM, et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 2004;350:29-37.  
  154. Psaty BM, Smith NL, Heckbert SR, et al. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 2002;287:1680-9.  
  155. Hines LM, Stampfer MJ, Ma J, et al. Genetic variation in alcohol dehydrogenase and the beneficial effect of moderate alcohol consumption on myocardial infarction. N Engl J Med 2001;344:549-55.  
  156. Herrington DM, Howard TD, Hawkins GA, et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med 2002;346:967-74.
  157. McKinnon WC, Baty BJ, Bennett RL, et al. Predisposition genetic testing for late-onset disorders in adults: a position paper of the National Society of Genetic Counselors. JAMA 1997;278:1217-20.  
  158. Kip KE, McCreath HE, Roseman JM, Hulley SB, Schreiner PJ. Absence of risk factor change in young adults after family heart attack or stroke: the CARDIA study. Am J Prev Med 2002;22:258-66.  
  159. Knutsen SF, Knutsen R. The Tromso survey: the family intervention study—the effect of intervention on some coronary risk factors and dietary habits, a 6-year follow-up. Prev Med 1991;20:197-212.  
  160. Randomised controlled trial evaluating cardiovascular screening and intervention in general practice: principal results of British family heart study. BMJ 1994;308:313-20.  
  161. Pyke SDM, Wood DA, Kinmonth AL, Thompson SG. Change in coronary risk and coronary risk factor levels in couples following lifestyle intervention. Arch Fam Med 1997;6:354-60.  
  162. Arnoff SL, Bennett PH, Gorden P, Rushforth N, Miller M. Unexplained hyperinsulinemia in normal and ‘prediabetic' Pima Indians compared with normal Caucasians. Diabetes 1977;26:827-40.  
  163. Sharp PS, Mohan V, Levy JC, Mather HM, Kohner EM. Insulin resistance in patients of Asian Indian and European origin with non-insulin dependent diabetes. Horm Metab Res 1987;19:84-5.  
  164. Rosendaal FR, Siscovick DS, Schwartz SM, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997;89:2817-21.  
  165. Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS. Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area: a histopathologic correlative study. Circulation 1995;92:2157-62.  
  166. Bielak LF, Rumberger JA, Sheedy PF, Schwartz RS, Peyser PA. Probabilistic model for prediction of angiographically defined obstructive coronary artery disease using electron beam computed tomography calcium score strata. Circulation 2000;102:380-5.  
  167. Nallamothu BK, Saint S, Rubenfire M, Fendrick AM. Electron beam computed tomography in the diagnosis of obstructive coronary artery disease. J Am Coll Cardiol 2001;37:689-90.  
  168. Arad Y, Spadaro LA, Goodman K, et al. Predictive value of electron beam computed tomography of the coronary arteries: 19-month follow-up of 1173 asymptomatic subjects. Circulation 1996;93:1951-3.  
  169. Secci A, Wong N, Tang W, Wang S, Doherty T, Detrano R. Electron beam computed tomographic coronary calcium as a predictor of coronary events: comparison of two protocols. Circulation 1997;96:1122-9.  
  170. Raggi P, Callister TQ, Cooil B, et al. Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography. Circulation 2000;101:850-5.  
  171. Detrano R, Hsiai T, Wang S, et al. Prognostic value of coronary calcification and angiographic stenoses in patients undergoing coronary angiography. J Am Coll Cardiol 1996;27:285-90.  
  172. He ZX, Hedrick TD, Pratt CM, et al. Severity of coronary artery calcification by electron beam tomography predicts silent myocardial ischemia. Circulation 2000;101:244-51.  
  173. Raggi P, Cooll B, Callister TQ. Use of electron beam tomography data to develop models for prediction of hard coronary events. Am Heart J 2001;141:372-82.  
  174. Wong ND, Detrano RC, Diamond G, et al. Does coronary artery screening by electron beam computed tomography motivate potentially beneficial lifestyle behaviors? Am J Cardiol 1996;78:1220-3.  
  175. Blankenhorn DH, Nessim SA, Johnson R, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;247:3233-40.  
  176. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993;119:969-76.  
  177. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.  
  178. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.  
  179. Jukema JW, Bruschke AVG, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-40.  
  180. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633-8.  
  181. Kreisberg RA. Cholesterol-lowering and coronary atherosclerosis: good news and bad news. Am J Med 1996;101:
    455-8.  
  182. Miller M. Niacin as a component of combination therapy for dyslipidemia. Mayo Clin Proc 2003;78:735-42.  
  183. Panagiotakos DB, Pitsavos C, Chrysohoou C, et al. Effect of leisure time physical activity on blood lipid levels: the ATTICA study. Coron Artery Dis 2003;14:533-9.  
  184. Chung BH, Doran S, Liang P, et al. Alcohol-mediated enhancement of postprandial lipemia: a contributing factor to an increase in plasma HDL and a decrease in risk of cardiovascular disease. Am J Clin Nutr 2003;78:391-9.  
  185. Schwartz ML. Severe reversible hyperglycemia as a consequence of niacin therapy. Arch Intern Med 1993;153:
    2050-2.  
  186. Smith CC, Bernstein LI, Davis RB, Rind DM, Shmerling RH. Screening for statin-related toxicity: the yield of transaminase and creatinine kinase measurements in a primary care setting. Arch Intern Med 2003;163:657-9.

arrow 1 | 2 | 3

Page last reviewed: June 8, 2007 (archived document)
Page last updated: September 10, 2007
Content Source: CDC's Office of Public Health Genomics